100 Campus Drive
Florham Park, NJ 07932
United States
608 441 8120
https://www.cellectar.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 20
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. James V. Caruso | President, CEO & Director | 1,14M | N/D | 1959 |
Mr. Chad J. Kolean CPA | VP, CFO & Secretary | 711,23k | N/D | 1964 |
Mr. Jarrod Longcor | Chief Operating Officer | 854,24k | N/D | 1973 |
Mr. Darrell Shane Lea | Chief Commercial Officer | N/D | N/D | 1974 |
Dr. Andrei Shustov M.D. | Senior Vice President of Medical | N/D | N/D | 1972 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
L'ISS Governance QualityScore di Cellectar Biosciences, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.